Global Alzheimer Drugs Market to Reach USD 6537.0 Million in 2021, Expected to Grow Due to Rising Prevalence of Alzheimer's Disease and Increasing Demand for Effective Therapies

Strategic Insights -

The global Alzheimer's drugs market is driven by the increasing prevalence of Alzheimer's disease, growth in the geriatric population, and rising demand for effective therapies. The market was valued at USD 6537.0 Million in 2021 and is expected to grow due to the expansion of telehealth services and the growing traction of online pharmacies.

Key Takeaways:

  • The global Alzheimer's drugs market was valued at USD 6537.0 Million in 2021 and is expected to grow due to the increasing prevalence of Alzheimer's disease and the growing demand for effective therapies.
  • The companies analyzed in the report include AbbVie Inc., F. Hoffman-La Roche, Ltd., Novartis AG, Biogen, Pfizer Inc., Eli Lilli and Company, Takeda Pharmaceutical Company Limited, Novo Nordisk, Daiichi Sankyo Company Ltd., Eisai Co. Ltd, and NervGen Pharma.
  • The market growth is driven by the expansion of telehealth services and the growing traction of online pharmacies, which have enabled disease diagnosis and drug delivery in remote regions.
  • Various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab and Solanezumab, which are expected to propel market growth in the coming years.
  • The increasing prevalence of Alzheimer's disease is fueling the demand for Alzheimer's drugs, driving the global Alzheimer's drugs market.
  • Rising R&D activities by pharmaceutical companies and research institutes for Alzheimer's effective therapy is expected to boost the global Alzheimer's drugs market.

Statistics:

  • The global Alzheimer's drugs market was valued at USD 6537.0 Million in 2021.
  • The market is expected to grow due to the increasing prevalence of Alzheimer's disease and the growing demand for effective therapies.
  • 14 companies are analyzed in the report, including AbbVie Inc., F. Hoffman-La Roche, Ltd., Novartis AG, Biogen, Pfizer Inc., Eli Lilli and Company, Takeda Pharmaceutical Company Limited, Novo Nordisk, Daiichi Sankyo Company Ltd., Eisai Co. Ltd, and NervGen Pharma.
  • 5 Alzheimer's drugs are currently under late-stage clinical trials, including Aducanumab and Solanezumab.

Sources:

  • "Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)" report on ResearchAndMarkets.com.
  • Businesswire.com article "Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)" dated February 8, 2022.